Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IL-2 Added to ECP for Steroid-Refractory Chronic GVHD
NCT02340676Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2015
- Primary completion
- Aug 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in chronic graft-versus-host disease (cGVHD), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Percentage of Participant With Response at 16 weeks. Started Feb 2015; status: completed.
02
Drugs
aldesleukin
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02340676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340676.